For the Inventor, By the Inventor

Enter assignee name

Fremont, CA, United States of America

Aryx Therapeutics, Inc.

USPTO Granted Patents = 50

EPO Patents = 2

Forward Citations = 221

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Pascal Jean Druzgala (47 out of 63 patents)

Peter G Milner (19 out of 41 patents)

Cyrus K Becker (14 out of 47 patents)

4. Xiaoming Zhang (9 out of 67 patents)

5. Jurg R Pfister (9 out of 43 patents)

6. Monica H Palme (4 out of 10 patents)

7. Ian Irwin (3 out of 10 patents)

8. Jinun-Ban Yeh (2 out of 10 patents)

9. Courtney Rubens (2 out of 2 patents)

10. Kolbot By (2 out of 2 patents)

11. Ponny Pang (2 out of 2 patents)

12. Jürg Pfister (2 out of 3 patents)

13. Jürg Roland Pfister (2 out of 12 patents)

14. Arthur John Cooper (1 out of 8 patents)

15. Jien-Heh J Tien (1 out of 1 patent)

Core Competencies:

Stereoisomeric Compounds

Gastrointestinal Disorders

Central Nervous System Disorders

Coagulation Disorders

5-HT3 Receptor Antagonists

Cardiac Arrhythmia

Ultrashort Acting Opioids

Hypnotic Barbiturates

Hypercholesterolemia

Diabetes Treatment

Transdermal Applications

Enantiomeric Compounds

50 patents: Sort by Forward Citations

1. 8138204 - Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders (2012-03-20),

2. 8093237 - Dibenzo[b,f][1,4]oxazapine compounds (2012-01-10),

3. RE42412 - Materials and methods for the treatment of gastroesophageal reflux disease (2011-05-30),

4. 7932405 - Halogenated ester derivatives of coumarins for the treatment of coagulation disorders (2011-04-26),

5. RE41289 - Ultrashort acting hypnotic barbiturates (2010-04-26),

6. 7666902 - Haloalkyl ester derivatives of coumarin for the treatment of coagulation disorders (2010-02-23),

7. 7629466 - Synthetic methods and intermediates for steroisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders (2009-12-08),

8. 7501436 - 5-HT3 receptor antagonists and methods of use (2009-03-10),

9. 7498449 - Antiarrhythmic precursor compounds, methods of synthesis and methods of use (2009-03-03),

10. 7384973 - Materials and methods for treating hypercholesterolemia (2008-06-10),

11. 7381735 - Ultrashort-acting opioids for transdermal application (2008-06-03),

12. 7351842 - Compounds for treatment of cardiac arrhythmia and methods of use (2008-04-01),

13. 7326787 - Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders (2008-02-05),

14. 7285671 - Materials and methods for treating coagulation disorders (2007-10-23),

15. 7282509 - Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders (2007-10-16),

ARYx Therapeutics, Inc. is a biopharmaceutical company that specializes in the development of novel small molecule drugs. They focus on addressing unmet medical needs in the cardiovascular and gastrointestinal fields. With a strong emphasis on research and development, ARYx Therapeutics aims to provide innovative solutions to improve patient outcomes. Visit their website for more information.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

50 Patents

#42 in Fremont, CA

#1,607 in California

#6,769 in US

#13,592 in the World

Fremont, CA, United States of America

Aryx Therapeutics, Inc.

Forward Citations = 221

17 inventors:

Pascal Jean Druzgala (47 out of 63 patents)

Peter G Milner (19 out of 41 patents)

Cyrus K Becker (14 out of 47 patents)

4. Xiaoming Zhang (9 out of 67 patents)

5. Jurg R Pfister (9 out of 43 patents)

Please report any incorrect information to support@idiyas.com

Loading…